Actinogen Medical Limited (ATGGF)
OTC Markets OTCPK · USD · Healthcare · Biotechnology
$0.035 (+0.00%) as of
Key statistics
- Market cap
- 135.60M
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.0008 – 0.0600
- Beta
- 0.83
- Revenue (TTM)
- 12.67M
- Profit margin
- -121.35%
- Volume
- 10.00k
About Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Sydney, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.